OpenLegislation

Regulation 4 Amendment of regulation 8

Original text. Later amendments are not shown.

In regulation 8(1)f1 (general interpretation), at the appropriate places insert—

  • ““EAMS medicinal product” means a medicinal product that—

    1. (a)

      has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and

    2. (b)

      remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D;”;

  • ““EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b);”;

  • ““EAMS scientific opinion holder” means the holder of a EAMS scientific opinion, and accordingly, is the person who places on the market the product to which the opinion relates;”;

  • ““Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1);”; and

  • ““EU Clinical Trials Regulation” means Regulation EU No. 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products, and repealing Directive 2001/20/ECf2;”.

Annotations

Footnotes

f1

Amended by S.I. 2013/1855 and 2593, 2015/534 and 1503, 2016/186, 190 and 696, 2017/715, 2018/199, 2019/62, 593, 703, 775 and 1094, 2020/349 and 1125 and 2021/1452.

f2

OJ L 158, 27.5.2014, p. 1.